Roche Holding stock gets a boost from giredestrant data

Published on 10/04/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock traded at CHF 345.70 on October 2, 2026, while giredestrant cut progression risk 44 percent in an ITT analysis. H1 sales rose 6 percent CER.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (CH1499059983) was last at CHF 345.70 on SIX on October 2, 2026, at 5:39 p.m. CEST, down 0.95 percent. On October 1, Roche reported that giredestrant plus everolimus reduced the risk of disease progression or death by 44 percent in the intent-to-treat population, according to Finanznachrichten.

Giredestrant delivers a clinical signal

The phase III evERA study showed median progression-free survival of 8.8 months with the Roche combination, compared with 5.5 months for standard endocrine therapy plus everolimus. In the ESR1-mutated population, the comparison widened to 10.0 months versus 5.5 months, with the risk of progression or death reduced by 62 percent.

The US Food and Drug Administration set November 30, 2026, as the PDUFA goal date for giredestrant in early-stage breast cancer and December 18, 2026, for advanced disease, according to Finanznachrichten.

Sales growth supports the pipeline

Roche's H1 2026 sales reached CHF 30.36 billion, up 6 percent at constant exchange rates, while core EPS increased 9 percent to CHF 10.85, according to Muffett Investments. The figures give the drug-development news a financial reference: Roche is combining established product sales with late-stage oncology catalysts.

Roche's investor page reports 2025 core EPS of CHF 19.46, representing 11 percent growth at constant exchange rates, and says 39 million patients received Roche medicines during that year, according to Roche.

Analysts keep a positive consensus

MarketBeat lists a Moderate Buy consensus from 12 analysts, including six Buy ratings and six Hold ratings, with an average target of USD 60.00 for Roche's ADR. The separate currency and listing mean that target is not compared with the SIX price.

Roche Holding stock stays below its yearly high

Roche Holding stock was last at CHF 345.70 on SIX on October 2, 2026, 8.01 percent below its 52-week high of CHF 375.80 and above its 52-week low of CHF 258.20. The market capitalization stood at CHF 275.1 billion, with 611,234 shares traded.